Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTIGA vs KHAPZORY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.
Lefamulin, a pleuromutilin antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the peptidyl transferase center (PTC) at the A-site cleft, thereby blocking peptide bond formation and protein translation.
Adjunctive therapy for partial-onset seizures in adults
Community-acquired bacterial pneumonia (CABP) in adults,Off-label: None established
100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.
KHAPZORY (lenalidomide) 25 mg orally once daily on days 1-21 of repeated 28-day cycles.
Terminal elimination half-life is approximately 13-16 hours in healthy individuals, allowing twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged (up to 30 hours).
Terminal elimination half-life: 15-20 hours; clinical context: supports once-daily dosing
Primarily glucuronidation by UGT1A9 and UGT2B7; minor CYP2E1 involvement.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP2D6 and CYP2C8; also undergoes conjugation and oxidation.
Renal excretion accounts for approximately 25-30% of the administered dose as unchanged drug; the remainder is eliminated as metabolites via the biliary/fecal route (up to 70%) and further metabolized. Total recovery in urine and feces is >90%, with fecal excretion being the major route.
Renal: 90% as unchanged drug; fecal: <5% as metabolites
Approximately 40% bound to albumin, mainly to albumin with minor binding to alpha-1-acid glycoprotein.
90-95% bound to albumin
Volume of distribution is approximately 0.7 L/kg, indicating distribution into total body water, and is consistent with low tissue binding.
0.3-0.4 L/kg; clinical meaning: distributes primarily into extracellular fluid
Oral bioavailability is approximately 90% (due to high absorption with minimal first-pass effect).
Oral: 70-85%
For Cr Cl 30-79 m L/min: 50 mg once daily for 1 week, then 100 mg twice daily; for Cr Cl 15-29 m L/min: 50 mg once daily for 1 week, then 50 mg twice daily; for Cr Cl <15 m L/min or hemodialysis: 50 mg once daily with post-dialysis supplementation of 50 mg.
Cr Cl ≥60 m L/min: 25 mg daily. Cr Cl 30-60 m L/min: 10 mg daily. Cr Cl <30 m L/min (not requiring dialysis): 15 mg every 48 hours. Cr Cl <30 m L/min (requiring dialysis): 5 mg once daily; on dialysis days, administer after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily for 1 week, then 100 mg twice daily; Child-Pugh C: not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Initiate at 10 mg daily. Child-Pugh Class C: Initiate at 5 mg daily; may titrate based on tolerance.
For children ≥4 years with partial-onset seizures: 1.5 mg/kg/day (maximum 50 mg/day) orally once daily for 1 week, then increase to 3 mg/kg/day (or 100 mg/day) in 2 divided doses for week 2, followed by 4.5 mg/kg/day (or 150 mg/day) in 2 divided doses for week 3, then maintenance of 6 mg/kg/day (or 200 mg/day) in 2 divided doses.
Safety and efficacy not established for patients <18 years; no recommended dosing.
Start at 50 mg once daily for 1 week, then increase to 50 mg twice daily; consider lower doses due to age-related renal impairment; monitor renal function.
No specific dose adjustment based on age alone; adjust for renal function as per renal adjustment guidelines; monitor for myelosuppression, thromboembolic events, and peripheral neuropathy more frequently.
None.
None
Neuropsychiatric symptoms (hallucinations, confusion, psychosis),Increased risk of suicidal thoughts/behavior,QT prolongation (dose-dependent),Urinary retention,PR interval prolongation,Hepatotoxicity
QTc interval prolongation (avoid in patients with known QTc prolongation, electrolyte disturbances, or concurrent use of QTc-prolonging agents),Hepatotoxicity (monitor liver function tests; discontinue if signs of liver injury occur),Clostridioides difficile-associated diarrhea (CDAD),Hypersensitivity reactions including anaphylaxis,Avoid use in patients with moderate to severe hepatic impairment (Child-Pugh B or C)
Hypersensitivity to ezogabine or any component,Concurrent use with other potassium channel openers (e.g., retigabine),Severe hepatic impairment (Child-Pugh C)
Hypersensitivity to lefamulin or any component of the formulation,Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) reduces lefamulin exposure; avoid coadministration
No significant food interactions reported. Take with or without food. Avoid alcohol and grapefruit juice as they may exacerbate CNS effects or affect metabolism.
No significant food interactions known. Avoid alcohol as it may increase risk of methotrexate toxicity.
POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester: potential for major malformations, but data insufficient. Second and third trimesters: risk of fetal toxicity and neonatal withdrawal. Should only be used if benefit outweighs risk.
KHAPZORY (levonorgestrel) is a progestin-only emergency contraceptive. Limited human data; no increased risk of major birth defects in case of inadvertent use during pregnancy. Theoretically, no known teratogenic effect in any trimester.
No data on excretion in human milk; M/P ratio unknown. Risk of infant sedation, poor feeding, and withdrawal. Caution advised; consider alternative therapies or discontinue breastfeeding.
Levonorgestrel is excreted into human milk; estimated infant dose < 1% of maternal dose. M/P ratio not reported. Generally considered compatible with breastfeeding.
Pregnancy can decrease ezogabine exposure due to increased clearance and volume of distribution; dose adjustments may be necessary to maintain efficacy. Monitor serum concentrations and clinical response, adjusting dose as needed. Postpartum, monitor for toxicity due to rapid clearance normalization and reduce dose accordingly.
Not indicated for use during pregnancy. No dose adjustment applicable.
Potiga (ezogabine/retigabine) is a neuronal potassium channel opener indicated as adjunctive treatment for partial-onset seizures. Requires ophthalmic monitoring due to risk of retinal pigment changes (blue-gray discoloration) and potential visual field defects. Urothelial effects (urinary retention, dysuria) are common; assess baseline renal function. QT prolongation possible; avoid with other QT-prolonging drugs. Titrate slowly to minimize CNS effects (dizziness, somnolence, ataxia).
KHAPZORY (levoleucovorin) is used as a rescue agent after high-dose methotrexate therapy to prevent severe toxicity. Monitor serum methotrexate levels closely; administer leucovorin until methotrexate level is <5×10^-8 M. Adjust dose in renal impairment. Not interchangeable with folic acid.
Take exactly as prescribed; do not abruptly stop therapy.,May cause dizziness or drowsiness; avoid driving until effects known.,Report any vision changes, eye pain, or blue-gray discoloration of skin/nails/retina.,Report difficulty urinating or blood in urine immediately.,Avoid alcohol and other CNS depressants.,Use effective contraception if applicable (can reduce hormonal contraceptive efficacy).,Store at room temperature (68-77°F) in original container.,Do not double dose if missed; contact doctor for missed dose instructions.
Take this medication exactly as prescribed, usually every 6 hours for a set number of doses.,Do not skip doses, as this may increase the risk of methotrexate toxicity.,Inform your doctor if you experience shortness of breath, rash, or signs of allergic reaction.,Keep all appointments for blood tests to monitor methotrexate levels.,Avoid taking folic acid supplements unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTIGA vs KHAPZORY, answered by our medical review team.
POTIGA is a Antiepileptic that works by Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.. KHAPZORY is a Antiepileptic that works by Lefamulin, a pleuromutilin antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the peptidyl transferase center (PTC) at the A-site cleft, thereby blocking peptide bond formation and protein translation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTIGA and KHAPZORY depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTIGA is: 100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.. The standard adult dose of KHAPZORY is: KHAPZORY (lenalidomide) 25 mg orally once daily on days 1-21 of repeated 28-day cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTIGA and KHAPZORY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTIGA is classified as Category C. POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester. KHAPZORY is classified as Category C. KHAPZORY (levonorgestrel) is a progestin-only emergency contraceptive. Limited human data; no increased risk of major birth defects in case of inadvertent use during pregnancy. The. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.